Category Archives: Immunology

Fight Misinformation With Anticipation, Facts, and Curiosity – Medscape

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

With the Delta variant taking hold and COVID cases on the rise in mid-July, US Surgeon General Vivek Murthy, MD, MBA, released an advisory declaring that misinformation was a serious health threat and urging Americans to help slow its spread during the pandemic and beyond.

Last weekend, speakers at the American College of Allergy, Asthma, and Immunology (ACAAI) 2021 Annual Meeting, in New Orleans, Louisiana, issued a similar call to arms. "We have to take advantage of the very special role that we all play in the lives of our patients," said David Stukus, MD, an allergist-immunologist and professor of clinical pediatrics at Nationwide Children's Hospital, Columbus, Ohio. "We want to use that trust that we've developed with them to help combat misinformation."

According to a poll conducted by the Kaiser Family Foundation, personal doctors and pediatricians topped the list of trusted sources for reliable COVID-19 vaccine information, Gerald Lee, MD, associate professor of pediatrics at Emory University School of Medicine, Atlanta, Georgia, told attendees.

Social media usage has soared over the past decade. Today, 7 in 10 Facebook users say they visit the site daily, and nearly 80% of Americans who regularly get news on Snapchat and TikTok view social media as an important source of vaccine news, according to Pew Research Center data that Lee presented at the meeting.

Although research shows that most people do a decent job discriminating truth from fake news, when it comes to sharing news on social media platforms, that discernment drops considerably. "Users share misinformation without considering accuracy," said Lee, citing a March 2021 study published in Nature. Social media algorithms tend to promote content that is emotionally engaging. This amplification allows "a small number of activists to achieve influence," Lee said. Their continued, repetitive messaging "perpetuates misinformation to being accepted by the public," he said.

Anne Ellis, MD, chair of allergy and immunology at Queen's University, in Kingston, Ontario, Canada, called for vigilance among allergy practitioners to fight the cycle of misinformation and not let fake news shape medical decision making. "Make facts your hook when you're talking to patients" and explain that "science is an evolving process," Ellis said at ACAAI.

"Providing facts not only helps patients trust and value their provider's input, but facts also help patients challenge anxiety-provoking information they may have learned via social media," Tamara Hubbard, LCPC, told Medscape Medical News. Hubbard, a licensed counselor in the Chicago area, works with food-allergy families and maintains a resource website that includes an international directory of allergy-informed clinical therapists.

Stukus encouraged physicians to anticipate patients' confusion and to be proactive about engaging people on these topics. "Ask questions," he said. "See if they have any concerns about health-related information or about things impacting their allergic conditions." Observe nonverbal cues, he said. For example, when asking patients whether they have concerns about the COVID vaccine, "they may say no, but their body may say something different." Then, he said, take time "to dive into the nuance."

In addition, he advised clinicians to bear in mind the fact that many patients have trouble comprehending risk and to seek different ways to convey health information. "It's one thing to say only five out of a million people have anaphylaxis to COVID vaccines," Stukus said. "You can also state that 999,995 people out of the million didn't have anaphylaxis when they got a COVID vaccine. Some people need to hear that."

He advised that when conversations wander into unfamiliar territory, one should be humble and transparent. If a patient throws a stumper, "I say, 'I honestly don't know. But you've given me an assignment that I'll happily take on, so I can give you the right information about that particular question you just asked,' " Ellis said.

Stukus has consulted for Before Brands, Integrity CE, and Kaleo; works as social media editor for the American Academy of Allergy, Asthma and Immunology (AAAAI) and is associate editor for Annals of Allergy, Asthma and Immunology; and receives honoraria from the American College of Allergy, Asthma and Immunology (ACAAI), the American Academy of Pediatrics, and AAAAI. Ellis has received an honorarium from AstraZeneca to give webinars on managing allergic and adverse reactions to COVID-19 vaccines. Lee reports no relevant financial relationships. Hubbard is an allied health member of ACAAI and AAAAI and completed a paid project for the nonprofit organization Food Allergy Research and Education.

American College of Allergy, Asthma, and Immunology (ACAAI) 2021 Annual Meeting: Presented November 6, 2021.

Esther Landhuis is a freelance science journalist in the San Francisco Bay Area. She can be found on Twitter @elandhuis.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Read this article:
Fight Misinformation With Anticipation, Facts, and Curiosity - Medscape

OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer…

Data presented at the 36th Annual Society for Immunotherapy of Cancer (SITC) Meeting

NANTES, France, November 15, 2021--(BUSINESS WIRE)--Regulatory News:

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) presented the first positive preclinical efficacy data on its novel myeloid cell immune checkpoint target, CLEC-1 (a C-type lectin receptor), at the Society for Immunotherapy of Cancer (SITC) 36 th Annual Meeting in Washington D.C. held in-person and virtually on November 10 14, 2021.

In the poster entitled: "Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology", OSE Immunotherapeutics and Dr Elise Chiffoleaus research team* reported results from their collaborative program, and for the first time highlighted significant preclinical efficacy of CLEC-1 antagonist antibodies in vivo and in monotherapy in an hepatocarcinoma tumor model in immunocompetent mice.

Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics, commented: "The identification of CLEC-1 and its antagonists is an exciting innovation in cancer immunotherapy, as already presented in recent immuno-oncology events. The latest preclinical efficacy data generated from our teams collaboration opens the development pathway for monoclonal antagonist antibodies targeting CLEC-1 and for further translational clinical development in the coming years as a new myeloid immune checkpoint therapy releasing the breaks on macrophages and dendritic cells. CLEC-1 is a new myeloid checkpoint inhibitor identified and validated for cancer immunotherapy after the CD47-SIRP pathway, which is now a competitive drug development focus."

CLEC-1 is a C-type lectin receptor with demonstrated potential to inhibit the functions of myeloid cells and to block anti-tumor responsiveness of T-lymphocytes. Myeloid cells have the ability to accumulate in the tumor microenvironment and deregulate the immune activation of T-lymphocytes.

Story continues

Previous presentations (AACR 2020 and 2021, SITC 2020) ** featured CLEC-1 antagonist monoclonal antibodies identified as an innovative immunotherapy that releases the brakes on macrophage phagocytosis and dendritic cells and demonstrates synergistic anti-cancer effects, in particular when paired with chemotherapy.

*Center for Research in Transplantation and Immunology, UMR1064, INSERM, Nantes University at Nantes University Hospital (CHU).

** AACR 2020 Virtual Annual Meeting II oral presentation details CLEC-1 suppress dendritic cell antigen presentation and is a novel myeloid immune checkpoint target for cancer immunotherapy.Drouin M, Saenz J, Evrard B, Gauttier V, Teppaz G, Lopez-Robles MD, Louvet C, Poirier N, Chiffoleau E

AACR 2020 Virtual Annual Meeting II poster details CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy controlling damaged and tumor cells phagocytosis.Gauttier V, Drouin M, Saenz J, Evrard B, Mary C,, Teppaz G, Desalle A, Thpenier V, Wilhelm E , Poirier N, Chiffoleau E

SITC 2020 Virtual Annual Meeting poster details CLEC-1 is a novel myeloid immune checkpoint controlling damaged and tumor cells phagocytosis.Gauttier V, Pengam S, Drouin M, Saenz J, Evrard B, Biteau K, Mary C,, Teppaz G, Desalle A, Thpenier V, Wilhelm E , Poirier N, Chiffoleau E

AACR 2021 Virtual Annual Meeting II CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation.Gauttier V., Pengam S., Drouin M., Saenz J., Evrard B., Mary C., Teppaz G., Desselle A., Thpenier V., Wilhelm E., Poirier N., Chiffoleau E.

ABOUT OSE ImmunotherapeuticsOSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The companys immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile:

Vaccine platform

- Tedopi (innovative combination of neoepitopes): the companys most advanced product; positive results for Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients after secondary resistance to checkpoint inhibitors.

In Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.

In Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.

In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.

- CoVepiT: a prophylactic second-generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results. Voluntary and temporary Phase 1 enrollment suspension on-going (July 2021).

Immuno-oncology platform

- BI 765063 (OSE-172, anti-SIRP mAb on CD47/SIRP pathway): developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy or in combination with ezabenlimab (PD-1 antagonist); Expansion Phase 1 open for screening.

- CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the "Dont Eat Me" signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.

- BiCKI: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.

Auto-immunity and inflammation platform

- FR104 (anti-CD28 monoclonal antibody): Licensing partnership agreement with Veloxis in the organ transplant market; ongoing Phase 1/2 in renal transplant (sponsored by the Nantes University Hospital); Phase 2-ready asset in an autoimmune disease indication.

- OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2a ongoing in Sjgrens syndrome (Servier sponsor).

- OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

For more information: https://ose-immuno.com/en/ Click and follow us on Twitter and LinkedIn

Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2021, including the annual financial report for the fiscal year 2020, available on the OSE Immunotherapeutics website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211114005024/en/

Contacts

OSE Immunotherapeutics Sylvie Dtrysylvie.detry@ose-immuno.com +33 153 198 757

Investor Relations Thomas Guillotthomas.guillot@ose-immuno.com +33 607 380 431

Media U.S. Media: LifeSci Communications Darren Opland, Ph.D.darren@lifescicomms.com +1 646 627 8387

French Media: FP2COM Florence Portejoiefportejoie@fp2com.fr +33 607 768 283

Guillaume van Renterghem LifeSci Advisorsgvanrenterghem@lifesciadvisors.com +41 76 735 01 31

Go here to see the original:
OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer...

Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunol – Benzinga

Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific

SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today announced the presentation of preclinical data for APVO603, the Company's bispecific antibody targeting 4-1BB (CD137) and OX40 (CD134), at the Society for Immunology in Cancers (SITC) 2021 Annual Meeting.

Poster #795 entitled, "APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIR technology designed to deliver a conditional T cell/NK response against solid tumors," will be presented and displayed on-site on Saturday, November 13th in Washington, D.C. Data in the poster showed that APVO603 enhanced dose-dependent control of in vitro tumor cell lysis when paired with a bispecific T-cell engager when compared either alone. Of note, investigators show that APVO603 has minimal impact on regulatory T cell suppression of CD8+ T cells' proliferation in vitro.

"APVO603 is a differentiated bispecific antibody with the potential to leverage the benefits of 4-1BB and OX40 in a single agent. Further, the tethering of molecules has the potential to reduce safety risks and improve potency profiles by targeting responses specifically to sites of active inflammation and limiting on-target toxicity," said Hilario Ramos, Senior Director of Immunobiology at Aptevo. "In addition, the data presented here demonstrate that this combination has the potential to promote anti-tumor responses two-fold. First, by improving the fitness of exhausted effector CD8+ T cells. Second, by reducing the potential for activation of suppressive responses by T regulatory subsets. This dual biological mechanism of action offers the potential for development of a compound that acts against both solid and hematologic tumors and in the presence of addition immunomodulatory treatments or modalities such as CAR T or adoptive immune cell therapies."

Aptevo CEO Marvin White commented, "We are very encouraged by the results reported in this poster, and we are excited to continue to develop APVO603 and provide this update on our progress as we work to advance the compound."

Title: APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIRTM technology designed to deliver a conditional T cell/NK response against solid tumors Presenter: Hilario Ramos, Senior Director of Immunobiology at AptevoDate/Time: Saturday, November 13, 2021

About APVO603

APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF Receptor Superfamily. Dual targeting of 4-1BB and OX40 provides synergistic co-stimulation of T cells with the potential to amplify the cytotoxic function of activated T cells and NK cells, potentially leading to more robust anti-tumor responses.

About Aptevo Therapeutics

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. Aptevo is seeking to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit http://www.aptevotherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy and safety of its therapeutic candidates and potential use of any such candidates as therapeutics for treatment of disease, advancement of its clinical trials and its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "optimism," "potential," "designed," "engineered," "breakthrough," "innovative," "innovation," "promising," "plans," "forecasts," "estimates," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.

There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social, and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation, enrollment and maintenance of patients, and completion of clinical trials, availability and timing of data from ongoing clinical trials, expectations for the timing and steps required in the regulatory review process, including our ability to obtain regulatory clearance to commence clinical trials, expectations for regulatory approvals, the impact of competitive products, actions of activist stockholders, our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19). These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.

CONTACTS:

InvestorsMiriam Weber MillerAptevo TherapeuticsEmail: IR@apvo.com or Millerm@apvo.comPhone: 206-859-6629

MediaJules AbrahamJQA PartnersEmail: jabraham@jqapartners.comPhone: 917-884-7378

SOURCE: Aptevo Therapeutics

View source version on accesswire.com: https://www.accesswire.com/672334/Aptevo-Therapeutics-Announces-Preclinical-Data-for-Bispecific-Antibody-APVO603-at-the-Society-for-Immunology-in-Cancer-Annual-Meeting

Follow this link:
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunol - Benzinga

Scipher Medicine to Present at the Jeffries London Healthcare Conference – Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced that Alif Saleh, Chief Executive Officer, and John Strumbos, Chief Financial Officer, will participate in the Jeffries London Healthcare Conference, November 16-19.

Scipher Medicine will present from London at 10 a.m. GMT on Tuesday, November 16, and management will be available for in-person and virtual investor meetings during the conference. A live webcast of the conference presentation will be available here.

About Scipher Medicine

Scipher Medicine, a precision immunology company matching patients with their most effective therapies, believes that patients deserve simple answers to treatment options based on scientifically backed data. Using spectra, our proprietary network medicine platform, and artificial intelligence, we commercialize blood tests revealing a persons unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. We partner with leading payers, providers, and pharmaceutical companies to bring precision medicine to autoimmune diseases. Visit http://www.sciphermedicine.com and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.

Link:
Scipher Medicine to Present at the Jeffries London Healthcare Conference - Business Wire

New Study Finds Evidence of COVID Antibodies in Breast Milk of Vaccinated Mothers – URMC

Immunity from both prior infection and vaccination produces antibody response in breast milk

A study published in JAMA Pediatrics co-authored by researchers at the University of Rochester Medical Center and New York University has found evidence that mothers with two types of immunity from COVID disease-acquired (those who have contracted COVID and recovered) and mRNA vaccination-acquired produced breast milk with active SARS-CoV-2 antibodies.

The study, titled Comparison of human milk antibody induction, persistence, and neutralizing capacity in response to SARS-CoV-2 infection versus mRNA vaccination was funded by The National Institute of Allergy and Infectious Diseases (NIAID) with in-kind support from Medela LLC. Samples were collected from 77 mothers - 47 in the infected group, 30 in the vaccine group to determine the level of antibodies in breast milk over time. Mothers who had disease-acquired immunity produced high levels of Immunoglobulin A (IgA) antibodies against the virus in breast milk, while vaccine-acquired immunity produced robust Immunoglobulin G (IgG) antibodies.

Samples of breast milk were infected with live SARS-CoV-2 virus, and both types of antibodies provided neutralization against SARS-CoV-2, the first time such evidence has been discovered for IgA and IgG antibodies, according to study co-author Bridget Young, Ph.D., assistant professor in the Division of Pediatric Allergy and Immunology at URMC.

Its one thing to measure antibody concentrations, but its another to say that antibodies are functional and can neutralize the SARS-CoV-2 virus, said Young, One of the exciting findings in this work is that breast milk from both mothers with COVID-19 infection, and from mothers receiving mRNA vaccination contained these active antibodies that were able to neutralize the virus.

Previous studies from URMC had shown evidence of antibodies in breast milk from COVID positive mothers. This follow-up study represents the longest time period that disease-acquired antibodies have been examined post-illness, and the results showed that these antibodies exist for three months after infection.

For vaccinated mothers, the study found evidence of a mild-to-modest decline in antibodies on average - three months post-vaccination.

The trend in breast milk antibodies aligns with what we see in vaccination sera, said study co-author Kirsi Jarvinen-Seppo, PhD, M.D., Chief of Pediatric Allergy and Immunology at URMC, after a few months, the antibodies trend downward, but the levels are still significantly above what they were pre-vaccine.

Both Young and Jarvinen-Seppo emphasize, however, that while the antibody response exists, its not yet shown whether these breast milk antibodies can provide protection against COVID for nursing children.

The study does not imply that children would be protected from illness, said Jarvinen-Seppo, and breast milk antibodies may not be a substitute for vaccination for infants and children, once approved.

For the next phase of the study, URMC researchers are looking to find evidence whether both vaccination and illness-acquired immunity provide antibodies against other seasonal coronaviruses.

Go here to read the rest:
New Study Finds Evidence of COVID Antibodies in Breast Milk of Vaccinated Mothers - URMC

Allergic Reactions to COVID Vaccines Rare and Do Not Preclude Immunization – Benzinga – Benzinga

AAAAI reinforces adverse allergic reaction to the vaccines is rare and mild when it does occur and should not deter individuals from being vaccinated.

MILWAUKEE (PRWEB) November 08, 2021

While individuals with a history of severe allergy are at higher risk for a reaction to the COVID-19 vaccine, those reactions are rare and should not preclude someone from getting vaccinated, recent studies show.

"The rate of anaphylaxis after the vaccine remains low and is readily treatable. The reactions that do occur, are mild, uncommon and do not interfere with receiving the vaccine," said Paul Williams, MD, FAAAAI, Emeritus Director with the Northwest Asthma and Allergy Center and Chair of the American Academy of Allergy, Asthma & Immunology (AAAAI) COVID-19 Response Task Force. "People with a confirmed history of an allergy to a component of one vaccine can receive another vaccine that does not contain that component."

Allergists are specifically trained to help people answer questions about vaccine safety and suggest approaches to vaccination that would be the safest for patients.

To speak with Dr. Williams or another allergy expert, please contact: media@aaaai.org.

The American Academy of Allergy, Asthma & Immunology also has a wealth of resources available on its COVID-19 Resources page.

Recent research on allergy and the COVID-19 vaccines:

The American Academy of Allergy, Asthma & Immunology (AAAAI) represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAI's Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

For the original version on PRWeb visit: https://www.prweb.com/releases/allergic_reactions_to_covid_vaccines_rare_and_do_not_preclude_immunization/prweb18319898.htm

Link:
Allergic Reactions to COVID Vaccines Rare and Do Not Preclude Immunization - Benzinga - Benzinga

Study offers insights on why the elderly are more susceptible to COVID-19 – Brown University

PROVIDENCE, R.I. [Brown University] Among the populations most significantly affected by COVID-19 are the elderly and patients with preexisting medical conditions including diabetes, hypertension, obesity, metabolic syndrome, cardiovascular disease and chronic lung diseases like COPD and asthma.

In a new study published in the journal JCI Insight, Brown University researchers describe the cellular and molecular events that explain why these groups have a higher risk of infection as well as of severe side effects and death.

This paper details a major discovery in COVID-19, said corresponding author Dr. Jack A. Elias, an immunologist and dean of medicine and biological sciences at Brown. It shows that levels of a protein called chitinase 3-like-1 increase with age as well as co-morbid diseases and infection. Whats more, chitinase 3-like-1 augments SARS CoV-2 infection.

The findings not only answer important questions about key mechanisms of the complex SARS-CoV-2 virus, Elias said, but also have direct implications for the development of therapeutics to control the viral infection.

Elias is part of a National Institutes of Health-funded laboratory that focuses on the cell and molecular biology of lung injury and repair. Researchers in the lab, including lead study author Suchitra Kamle and co-author Chun Geun Lee, have recently focused on the biology of enzymes and enzyme-like molecules, called chitinases and chitinase-like proteins, respectively. Of particular interest is a chitinase-like protein referred to as chitinase 3-like-1, a molecule naturally found in blood.

Weve been studying this gene family here at Brown for a while and we know that it has a large number of biologic effects, as well as tremendously important roles in both health and diseases, said Lee, a professor (research) of molecular microbiology and immunology.

Chitinase 3-like-1 is the cornerstone of a critical pathway that is activated during injury and inflammation. These researchers and others have shown that circulating levels of chitinase 3-like-1 increase during infection, especially in diseases characterized by inflammation and tissue alterations like emphysema, asthma and COPD, some the same co-morbid diseases that are risk factors for COVID-19.

Interestingly, Lee said, levels of chitinase 3-like-1 have also been shown to increase during normal aging. In fact, they have been reported to be the best predictor of all-cause mortality in people in their 80s.

The researchers thought they might be able to take some of the work theyve already done with this gene family and apply it to COVID-19, Elias said. They decided to examine the relationship between chitinase 3-like-1 and the receptor ACE2, the spike protein to which the SARS-CoV-2 binds to enter human cells.

In a series of studies, the researchers compared the effects of chitinase 3-like-1 on ACE2 as well as on other protease enzymes that metabolize the spike protein and contribute to infection. They examined these interactions in the lungs of mice that were genetically modified to have exaggerated levels of chitinase 3-like-1 as well as mice deficient in chitinase 3-like-1. In the lab, Kamle led experiments that examined the effects of chitinase 3-like-1 on human lung epithelial cells.

The researchers found that levels of chitinase 3-like-1 increased with age, co-morbid diseases and infection. In addition, they noted that chitinase 3-like-1 was a potent stimulator of the receptor that SARS-CoV-2 uses to infect cells.

Spurred by this discovery, the researchers developed a humanized monoclonal antibody called FRG that attacks a particular region of chitinase 3-like-1 a step that turned out to be critical. They found that this therapeutic antibody, as well as another small molecule, powerfully blocked the induction of the ACE2 receptor.

So in that way, the virus cannot enter into the host system, said Kamle, a Brown investigator in molecular microbiology and immunology as well as antibody engineering. This means there will be less infection in the presence of this therapeutic FRG antibody.

These findings could pave the way for the development of therapeutics to protect people from infection, Elias said.

You can imagine a scenario in which someone who has been exposed to a person who has the virus is given the antibody, which then acts like a prophylactic to prevent infection or make the symptoms that the infection induces milder, he said.

Elias described another potential scenario in which the person who has the virus is given the antibody or the small molecule, which halts the infection and effectively cures the illness.

We show in this paper that if we make antibodies or other small molecules that can inhibit chitinase 3-like-1, they can be therapeutics to control viral infection, Elias said.

The team is currently looking at how these antibodies and small molecules react with different variants of the SARS CoV-2 virus, including the infectious delta variant that has recently changed the course of the pandemic.

In addition to Elias, Kamle and Lee, other Brown faculty who contributed to this research included Bing Ma, Chuan Hua He, Bedia Akosman, Yang Zhou, Chang Min Lee, Wafik S. El-Deiry, Kelsey Huntington and Olin Liang.

This work was supported by COVID-19 Research Seed Grant from Brown University, as well as by National Institute of Health grants U01 HL108638, PO1 HL114501,R01 HL115813 and RO1 AG053495, as well as grant USAMRMCW81XWH-17-1-0196 from the U.S. Department of Defense.

See the article here:
Study offers insights on why the elderly are more susceptible to COVID-19 - Brown University

Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market…

PHOENIX, Nov. 9, 2021 /PRNewswire/ --(OTC-CELZ)Creative Medical Technology Holdings, Inc. (the "Company"), a commercial stage biotechnology company focused on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications, today announced its intention to effect a 1-for-500 reverse split of its common stock in preparation for a planned listing of the Company's securities on The Nasdaq Capital Market ("Nasdaq"). The reverse stock split will become effective at the open of business on Wednesday, November 10, 2021, and the Company's common stock will begin trading on the OTC Markets system on a split-adjusted basis under the temporary ticker symbol "CELZD" at that time. The fifth character "D" will remain appended to the Company's symbol for 20 business days or until the Company is listed on Nasdaq, whichever comes first, at which point the Company's trading symbol will revert back to "CELZ." The new CUSIP number for the Company's common stock is 22529Y 309.

The Company has filed an application to list its common stock and warrants on Nasdaq. The reverse stock split is intended to enable the Company to meet the stock price requirement for initial listing on The Nasdaq Capital Market.

"Our plan to list on the Nasdaq Capital Market is an important step forward for the Company. We believe that a listing on Nasdaq will raise our profile to the broader investment community, and ultimately create shareholder value," stated Timothy Warbington, Chief Executive Officer.

Upon effectiveness of the reverse stock split, every 500 shares of the Company's common stock outstanding will be converted into one share of common stock, with any fractional shares rounded up to one whole share. Accordingly, the number of shares of common stock outstanding following the reverse stock split will be reduced from 1,226,141,742 shares to 2,452,348 shares. The reverse split will uniformly impact all stockholders, as it will not alter any stockholder's percentage equity interest in the Company, and not result in any dilution, except to the extent that the reverse split results in a stockholder owning a fractional share.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is currently listed on the OTC under the ticker symbol CELZ. For further information about the company go to http://www.creativemedicaltechnology.com.

Forward-Looking Statements

This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers, obtaining necessary regulatory approvals, enrollment of adequate numbers of patients in clinical trials, and unforeseen difficulties in showing efficacy of the company's products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

http://www.creativemedicaltechnology.comwww.CaverStem.comwww.FemCelz.comwww.StemSpine.comwww.immcelz.com

SOURCE Creative Medical Technology Holdings, Inc.

Home

Continue reading here:
Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market...

Federal funding to aid expansion of Hamilton-based lab studying vaccine-related blood clots – Global News

A McMaster University laboratory combating vaccine-related blood clots is getting a boost from the federal government to expand its testing centre.

The $1.5-million grant from the Public Health Agency of Canada earmarked for McMasters Platelet Immunology Laboratory (MPIL) will aid studies on vaccine-induced thrombotic thrombocytopenia(VITT), identified in a small number ofCOVID-19vaccine recipients.

Story continues below advertisement

The affliction came to the forefront amid the pandemic when VITT was associated with some 30 patients and five deaths in Canada but not definitively linked to the viral vector shots from Oxford-AstraZeneca and Johnson & Johnson.

According to the Ontario Science Table, a VITT case usually presents itself between four and 28 days after vaccination.

Hamilton-based researchers have been collecting blood samples from VITT patients for diagnostic testing with the emergence of the problem in the hopes of devising treatments based on the previous study of heparin-induced thrombocytopenia (HIT) a disorder tied to the clumping of platelets in the blood causing clots.

This expansion of world-class rapid laboratory testing here in Canada for suspected Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) cases will provide expertise to our international partners, and support Canadas robust vaccine safety surveillance systems, federal Minister of Health Jean-Yves Duclos said in a statement.

Story continues below advertisement

Ishac Nazy, scientific director of the lab and associate professor of medicine, says the research will also support foreign labs not equipped to diagnose and treat VITT.

This lab is uniquely positioned as a true translational medical facility; we research disease mechanisms using patient blood samples. This allows us to devise diagnostic testing and new therapies that have already saved patients lives, Nazy said in a release.

Canada has had few new cases of VITT since late May after several provinces, including Ontario, decreased usage of the vaccine.

However, co-medical director of the lab Donald Arnold said the MPIL has been handling patient blood samples from abroad, most recently Brazil.

We are well-positioned as a national repository of data and the reference laboratory, to serve both our country and the world in surveillance, diagnosis and treatment of VITT, Arnold said

Clinicians are still on high alert for clotting caused by adenovirus-vector vaccines.

2021 Global News, a division of Corus Entertainment Inc.

Read this article:
Federal funding to aid expansion of Hamilton-based lab studying vaccine-related blood clots - Global News